September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The Shot-term Outcomes of Treat and Extend Regimens: Aflibercept versus Ranibizumab
Author Affiliations & Notes
  • Kwan Bok Lee
    Ophthalmology, Kim's eye hospital, Seoul, Seoul, Korea (the Republic of)
  • Jung-Il Han
    Ophthalmology, Kim's eye hospital, Seoul, Seoul, Korea (the Republic of)
  • Dong-Won Lee
    Ophthalmology, Kim's eye hospital, Seoul, Seoul, Korea (the Republic of)
  • Moon-Jung Choi
    Ophthalmology, Kim's eye hospital, Seoul, Seoul, Korea (the Republic of)
  • Young Ju Lew
    Ophthalmology, Kim's eye hospital, Seoul, Seoul, Korea (the Republic of)
  • Hyung-Suk Kim
    Ophthalmology, Kim's eye hospital, Seoul, Seoul, Korea (the Republic of)
  • Han-Joo Cho
    Ophthalmology, Kim's eye hospital, Seoul, Seoul, Korea (the Republic of)
  • Jae-Hui Kim
    Ophthalmology, Kim's eye hospital, Seoul, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Kwan Bok Lee, None; Jung-Il Han, None; Dong-Won Lee, None; Moon-Jung Choi, None; Young Ju Lew, None; Hyung-Suk Kim, None; Han-Joo Cho, None; Jae-Hui Kim, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 540. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Kwan Bok Lee, Jung-Il Han, Dong-Won Lee, Moon-Jung Choi, Young Ju Lew, Hyung-Suk Kim, Han-Joo Cho, Jae-Hui Kim; The Shot-term Outcomes of Treat and Extend Regimens: Aflibercept versus Ranibizumab
      . Invest. Ophthalmol. Vis. Sci. 2016;57(12):540.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the short-term outcomes of “treat and extend” regimens with aflibercept versus with ranibizumab in wet age-related maculardegeneration patients.

Methods : This prospective study enrolled 23 patients with wet age-related macular degeneration (ARMD) who divided into two groups, a treat and extend (TAE) regimen with ranibizumab group (Group 1, n=13) and a same regimen with aflibercept group (Group 2, n=10). The central macular thickness (CMT) measured with spectral domain (SD) optical coherence tomography (OCT). We compared the mean gains in best-corrected visual acuity (VA) as well as the mean decreases of CMT.

Results : Two groups hadno significant differences in baseline characteristics including age, visual acuity, CMT, and presences of intraretinal or subretinal fluid at initial presentation. At 8 months, the VA (LogMAR) was significantly improved (Group 1: -0.17 ± 0.16, and group 2: -0.16 ± 0.21) and the CMT was significantly decreased (Group 1: -193.23 ± 165.91 µm, and group 2: -152.10±144.19 µm) in each groups, but there is no significant difference between the two groups. One patient of group 1 was worsened in VA, and two patients of group 1 showed recurrence, but those are not statistically significant. And at last follow up, Group 2 showed less intraretinal or subretinal fluid.

Conclusions : The treat and extend regimens with aflibercept and ranibizumab significantly improved VA and decreased CMT in patients with ARMD.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×